Pervasis Therapeutics, Inc.

Regenerative medicine, while not a new area of medical research, has advanced within the last several years to emerge as one of the best hopes for addressing, and even curing, diseases that until now

Shire Pharmaceuticals is known for its acquisitive buy-late, maximize-market strategy. Flemming Ornskov, the company's new CEO, plans to continue that approach, firstly by applying it to acquisitions

When Shire PLC created Shire Regenerative Medicine Inc. around the purchase of Advanced BioHealing Inc. (ABH) in 2011, it became the first major pharmaceutical or device company in some time t

The evolution of Shire's entrepreneurial regenerative medicine business continues with the appointment of Jeff Jonas as president of the division, which has been headquartered in San Diego, US since t